Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Lack of association between soluble CD40L and risk in a large cohort of patients with acute coronary syndrome in OPUS TIMI-16

Abstract

Background Previous studies have suggested that elevated soluble CD40 ligand (sCD40L) levels predict adverse cardiovascular outcomes in patients with acute coronary syndromes (ACS). Recently, questions have been raised regarding the influence of pre-analytical and analytical conditions on measurement of sCD40L, and additional studies have had conflicting findings regarding the prognostic value of this marker. Methods and Results We measured levels of sCD40L in citrated plasma using an analytically validated automated immunoassay (Roche Diagnostics) in a large cohort of ACS patients (n = 2403) from the placebo arm of the OPUS TIMI-16 trial. No association was observed between elevated sCD40L levels and risk of death or myocardial infarction (MI) (Quartile 1, 8.0%; Quartile 2, 11.7%; Quartile 3, 8.2%; Quartile 4, 6.8%; P = 0.54) or risk of death, MI or heart failure at 10 months (Quartile 1, 9.9%; Quartile 2, 14.2%; Quartile 3, 10.9%; Quartile 4, 8.3%; P = 0.55). A comparison of plasma vs. serum measurements of sCD40L was performed on samples from a nested case–control analysis (n = 42) from within this cohort. Median sCD40L levels did not differ between cases and controls using plasma (0.23 ng/ml vs. 0.27 ng/ml, respectively; P = 0.82) or serum samples (0.64 vs. 0.77, respectively; P = 0.85). Serum samples consistently yielded elevated sCD40L measurements compared to plasma samples (median value 0.72 ng/ml vs. 0.25 ng/ml, respectively, P < 0.001). Conclusions The absence of an association between sCD40L and cardiovascular outcomes in a large cohort of patients with ACS raises concern regarding the reproducibility of clinical results with this novel biomarker. Despite a plausibly important role in the pathobiology of atherothrombosis, pre-analytic sources of variability may limit the practical clinical application of sCD40L.

This is a preview of subscription content, log in to check access.

Fig. 1
Fig. 2
Fig. 3

References

  1. 1.

    Hansson GK, Libby P (2006) The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol 6:508–519

  2. 2.

    Apple FS, Wu AH, Mair J et al (2005) Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome. Clin Chem 51:810–824

  3. 3.

    Mach F, Schonbeck U, Libby P (1998) CD40 signaling in vascular cells: a key role in atherosclerosis? Atherosclerosis 137(Suppl):S89–S95

  4. 4.

    Mach F, Schonbeck U, Sukhova GK et al (1997) Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40-CD40 ligand signaling in atherosclerosis. Proc Natl Acad Sci USA 94:1931–1936

  5. 5.

    Henn V, Slupsky JR, Grafe M et al (1998) CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 391:591–594

  6. 6.

    Aukrust P, Muller F, Ueland T et al (1999) Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation 100:614–620

  7. 7.

    Kinlay S, Schwartz GG, Olsson AG et al (2004) Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study. Circulation 110:386–391

  8. 8.

    Heeschen C, Dimmeler S, Hamm CW et al (2003) Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 348:1104–1111

  9. 9.

    Varo N, de Lemos JA, Libby P et al (2003) Soluble CD40L: risk prediction after acute coronary syndromes. Circulation 108:1049–1052

  10. 10.

    Schonbeck U, Varo N, Libby P, Buring J, Ridker PM (2001) Soluble CD40L and cardiovascular risk in women. Circulation 104:2266–2268

  11. 11.

    Bereczki D, Nagy E, Pal A, Magyar MT, Balla J (2003) Should soluble CD40 ligand be measured from serum or plasma samples? Arterioscler Thromb Vasc Biol 23:1129–1130; author reply 1130–1131

  12. 12.

    Ahn ER, Lander G, Jy W et al (2004) Differences of soluble CD40L in sera and plasma: implications on CD40L assay as a marker of thrombotic risk. Thromb Res 114:143–148

  13. 13.

    Halldorsdottir AM, Stoker J, Porche-Sorbet R, Eby CS (2005) Soluble CD40 ligand measurement inaccuracies attributable to specimen type, processing time, and ELISA method. Clin Chem 51:1054–1057

  14. 14.

    Nannizzi-Alaimo L, Rubenstein MH, Alves VL, Leong GY, Phillips DR, Gold HK (2002) Cardiopulmonary bypass induces release of soluble CD40 ligand. Circulation 105:2849–2854

  15. 15.

    Thom J, Gilmore G, Yi Q, Hankey GJ, Eikelboom JW (2004) Measurement of soluble P-selectin and soluble CD40 ligand in serum and plasma. J Thromb Haemost 2:2067–2069

  16. 16.

    Weber M, Rabenau B, Stanisch M et al (2006) Influence of sample type and storage conditions on soluble CD40 ligand assessment. Clin Chem 52:888–891

  17. 17.

    Varo N, Nuzzo R, Natal C, Libby P, Schonbeck U (2006) Influence of pre-analytical and analytical factors on soluble CD40L measurements. Clin Sci (Lond) 111:341–347

  18. 18.

    Ivandic BT, Spanuth E, Haase D, Lestin HG, Katus HA (2007) Increased plasma concentrations of soluble CD40 ligand in acute coronary syndrome depend on in vitro platelet activation. Clin Chem 53:1231–1234

  19. 19.

    Cannon CP, McCabe CH, Wilcox RG et al (2000) Oral glycoprotein IIb/IIIa inhibition with orbofiban in patients with unstable coronary syndromes (OPUS-TIMI 16) trial. Circulation 102:149–156

  20. 20.

    Morrow DA, de Lemos JA (2007) Benchmarks for the assessment of novel cardiovascular biomarkers. Circulation 115:949–952

  21. 21.

    Pearson TA, Mensah GA, Hong Y, Smith SC Jr (2004) CDC/AHA Workshop on markers of inflammation and cardiovascular disease: application to clinical and public health practice: overview. Circulation 110:e543–e544

  22. 22.

    Lip GY, Patel JV, Hughes E, Hart RG (2007) High-sensitivity C-reactive protein and soluble CD40 ligand as indices of inflammation and platelet activation in 880 patients with nonvalvular atrial fibrillation. Relationship to stroke risk factors, stroke risk stratification schema, and prognosis. Stroke

Download references

Acknowledgments

The TIMI study group has received grant support from Searle for the performance of the OPUS TIMI-16 study. Roche provided reagents and grant support for analysis of sCD40L.

Author information

Correspondence to Benjamin A. Olenchock.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Olenchock, B.A., Wiviott, S.D., Murphy, S.A. et al. Lack of association between soluble CD40L and risk in a large cohort of patients with acute coronary syndrome in OPUS TIMI-16. J Thromb Thrombolysis 26, 79 (2008). https://doi.org/10.1007/s11239-007-0156-z

Download citation

Keywords

  • Soluble CD40L
  • Acute coronary syndromes
  • OPUS
  • TIMI-16
  • Biomarkers